Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Medtronic is poised to significantly deepen its interventional cardiology footprint with the potential acquisition of CathWorks, an Israel-based medtech innovator specializing in AI-driven coronary physiology assessment.</li><li>After entering into a strategic partnership back in 2022, Medtronic recently announced it will exercise its option to acquire CathWorks for up to $585 million, pending regulatory approvals.</li><li>CathWorks’ flagship FFRangio® System leverages artificial intelligence and computational modeling to derive Fractional Flow Reserve (FFR) measurements from standard angiograms without the need for invasive pressure wires or vasodilator drugs.</li></ul>

Medtronic is poised to significantly deepen its interventional cardiology footprint with the potential acquisition of CathWorks, an Israel-based medtech innovator specializing in AI-driven coronary physiology assessment.After entering into a strategic partnership back in 2022, Medtronic recently announced it will exercise its option to acquire CathWorks for up to $585 million, pending regulatory approvals.CathWorks’ flagship FFRangio® System leverages artificial intelligence and computational modeling to derive Fractional Flow Reserve (FFR) measurements from standard angiograms without the need for invasive pressure wires or vasodilator drugs.

Medtronic's Acquisition Of Cathworks: Its SMARTEST Move in AI Cardiology?

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Sahajanand Medical Technologies / Equity Bottom-Up

Sahajanand Medical Technologies (2585275D IN)

<ul>
<li>SMT plans to open its IPO on 15 October 2026 through an offer for sale (OFS) of approximately 1.38 crore equity shares, with no fresh capital raised by the issuer.</li>
<li>FY26 revenue from operations reportedly reached Rs. 1,210.5 crore, up 18.1%; PAT reached Rs. 69.1 crore versus Rs. 25.15 crore in FY25. </li>
<li>SMT has meaningful international exposure, a clinically specialised product portfolio and a growing structural-heart business.</li>
</ul>


SMT plans to open its IPO on 15 October 2026 through an offer for sale (OFS) of approximately 1.38 crore equity shares, with no fresh capital raised by the issuer.
FY26 revenue from operations reportedly reached Rs. 1,210.5 crore, up 18.1%; PAT reached Rs. 69.1 crore versus Rs. 25.15 crore in FY25. 
SMT has meaningful international exposure, a clinically specialised product portfolio and a growing structural-heart business.


Sahajanand Medical Technologies IPO: Global Stent Franchise, Emerging Structural Heart Opportunity

<ul><li>Medtronic presented its Q2 fiscal 2026 earnings, reporting a notable quarter with revenue and EPS exceeding market expectations.</li><li>The company recorded revenue growth of 6.6% on a reported basis and an organic increase of 5.5%, driven by solid performance across key business areas.</li><li>Specifically, Cardiac Ablations led the way with a 71% growth, largely attributed to the expansion of its Pulsed Field Ablation (PFA) franchise.</li></ul>

Medtronic presented its Q2 fiscal 2026 earnings, reporting a notable quarter with revenue and EPS exceeding market expectations.The company recorded revenue growth of 6.6% on a reported basis and an organic increase of 5.5%, driven by solid performance across key business areas.Specifically, Cardiac Ablations led the way with a 71% growth, largely attributed to the expansion of its Pulsed Field Ablation (PFA) franchise.

Medtronic: Is Symplicity Renal Denervation the Next Breakout Growth Engine?

Quality-first, Business-perspective, Long-term, Urbem (HK) Limited

Urbem Capital

Quality-first, Business-perspective, Long-term

Quality-first, Business-perspective Strategy

Urbem (HK) Limited

<ul>
<li>Eighteen S&amp;P 500 giants earned 20%-plus ROE through the 1990s; fourteen then trailed the index into 2026, the median by about 2.7 points a year.</li>
<li>Rich starting multiples, maturing runways, eroding moats and costly deals did the damage, while leverage and buybacks had flattered some of the returns on capital.</li>
<li>Microsoft renewed its runway and Altria started cheap; today's high-return screens should ask whether returns are still rising and whether the price still allows low-teens returns.</li>
</ul>


Eighteen S&amp;P 500 giants earned 20%-plus ROE through the 1990s; fourteen then trailed the index into 2026, the median by about 2.7 points a year.
Rich starting multiples, maturing runways, eroding moats and costly deals did the damage, while leverage and buybacks had flattered some of the returns on capital.
Microsoft renewed its runway and Altria started cheap; today's high-return screens should ask whether returns are still rising and whether the price still allows low-teens returns.


After They Were Giants: Why 2000's High-Return Stocks Mostly Lagged for 25 Years

Founder at Stock Spin-off Investing, Stock Spin-Off Investing

Richard Howe

Founder at Stock Spin-off Investing

Stock Spin-Off Investing

Generate attractive returns by taking advantage of inefficiencies in the stock spin-off market.

Stock Spin-offs

Event-Driven

<ul>
<li>This week, Corteva and Vylor hosted their respective analyst days.</li>
<li>Corteva also set the distribution ratio (1:1) for the spin-off, announced a ticker (VYLR), and confirmed expected regular way trading (10/1/2026).</li>
<li>Meanwhile, Medtronic announced it would distribute its ~90% stake in its diabetes business, MiniMed (MMED), through an exchange offer (MDT shareholders get to decide which stock they want to own).</li>
</ul>


This week, Corteva and Vylor hosted their respective analyst days.
Corteva also set the distribution ratio (1:1) for the spin-off, announced a ticker (VYLR), and confirmed expected regular way trading (10/1/2026).
Meanwhile, Medtronic announced it would distribute its ~90% stake in its diabetes business, MiniMed (MMED), through an exchange offer (MDT shareholders get to decide which stock they want to own).


United States

Medtronic, PLC develops therapeutic and diagnostic medical products. The Company's principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic's products are sold worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medtronic (MDT UN)

Medtronic's Acquisition Of Cathworks: Its SMARTEST Move in AI Cardiology?

Medtronic is poised to significantly deepen its interventional cardiology footprint with the potential acquisition of CathWorks, an Israel-based...

Baptista Research

Sahajanand Medical Technologies IPO: Global Stent Franchise, Emerging Structural Heart Opportunity

Sahajanand Medical Technologies’ profits surged 175% in FY26, but rising debt and modest returns raise questions. Can its global medical-device...

Sudarshan Bhandari

Medtronic: Is Symplicity Renal Denervation the Next Breakout Growth Engine?

Medtronic presented its Q2 fiscal 2026 earnings, reporting a notable quarter with revenue and EPS exceeding market expectations. The company...

Baptista Research

After They Were Giants: Why 2000's High-Return Stocks Mostly Lagged for 25 Years

In 2000, America's highest-return giants looked like the safest quality stocks. Most then lagged the market for 25 years. Several warning signs...

Urbem Capital

Weekly Update (MMED, MDT, ZD)

This week, Corteva and Vylor hosted their respective analyst days. Corteva also set the distribution ratio (1:1) for the spin-off...

Richard Howe

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)